Platten M, Linnemann R, Kümmerle T, Jung N, Wyen C, Ehren K, Gravemann S, Gillor D, Cornely O A, Fischer J, Lehmann C, Rockstroh J K, Fätkenheuer G, Vehreschild J J
Department of Internal Medicine I, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany,
Infection. 2014 Oct;42(5):849-57. doi: 10.1007/s15010-014-0646-9. Epub 2014 Jun 26.
Little data exist about the quality of care for HIV-infected subjects in Germany. We investigated the clinical course of HIV-infected subjects newly presenting in our HIV outpatient clinic.
Antiretroviral therapy (ART)-naïve HIV-infected subjects presenting between 2007 and 2008 were followed until June 2012. Clinical data and laboratory parameters were collected prospectively and analysed retrospectively.
From 281 subjects included, 34 patients (12%) were lost to follow-up. 247 subjects remained, and 171 patients were followed for 1,497 days [1,121/1,726] (all data: median [interquartile range]). ART was started in 199 patients (81%) 182 days [44/849] after HIV diagnosis, and all patients were treated according to European guidelines or within clinical trials. The CD4 cell count at first presentation was 320/µL [160/500] and declined to 210/µL [100/300] at ART start. 12 months thereafter, the CD4 cell count increased to 410/µL [230/545]. The HIV RNA was suppressed below 50 copies/mL after 108 days [63/173] in 182 patients (91%). Initial ART was changed in 71 patients (36%) after 281 days [99/718], in five patients (7%) due to virological failure, in 66 patients (93%) due to other reasons, e.g. side effects or patient's request.
Two-thirds of the included patients were followed for more than 3 years, and ART was initiated in 81% of the patients leading to complete virological suppression in most patients. Compliance of physicians with treatment guidelines was high. Late presentation with a severely compromised immune function remains a problem and impairs the otherwise good prognosis of HIV infection.
关于德国艾滋病毒感染者的护理质量,现有数据较少。我们对新到我们艾滋病毒门诊就诊的艾滋病毒感染者的临床病程进行了调查。
对2007年至2008年间初治抗逆转录病毒疗法(ART)的艾滋病毒感染者进行随访,直至2012年6月。前瞻性收集临床数据和实验室参数,并进行回顾性分析。
纳入的281名受试者中,34名患者(12%)失访。247名受试者留存,171名患者随访了1497天[1121/1726](所有数据:中位数[四分位间距])。199名患者(81%)在艾滋病毒诊断后182天[44/849]开始接受ART治疗,所有患者均按照欧洲指南或在临床试验中接受治疗。首次就诊时CD4细胞计数为320/µL[160/500],开始ART治疗时降至210/µL[100/300]。此后12个月,CD4细胞计数升至410/µL[230/545]。182名患者(91%)在108天[63/173]后艾滋病毒RNA被抑制至低于50拷贝/mL。71名患者(36%)在281天[99/718]后更改了初始ART治疗方案,其中5名患者(7%)因病毒学失败,66名患者(93%)因其他原因,如副作用或患者要求。
三分之二的纳入患者随访超过3年,81%的患者开始接受ART治疗,多数患者实现了病毒学完全抑制。医生对治疗指南的依从性较高。免疫功能严重受损的晚期就诊仍是一个问题,影响了艾滋病毒感染原本良好的预后。